Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 3Endometrial Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Melanoma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Bites and Stings 1Adenocarcinoma 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × dostarlimab × Clear all
NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Tesaro, Inc.

Phase 1 Active not recruiting
463 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡